Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy

Neuropharmacology. 2020 May 1:167:107734. doi: 10.1016/j.neuropharm.2019.107734. Epub 2019 Aug 1.

Abstract

Traumatic brain injury (TBI) and status epilepticus (SE) have both been linked to development of human epilepsy. Although distinct etiologies, current research has suggested the convergence of molecular mechanisms underlying epileptogenesis following these insults. One such mechanism involves the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tropomyosin related kinase B (TrkB). In this review, we focus on currently available data regarding the pathophysiologic role of BDNF/TrkB signaling in epilepsy development. We specifically examine the axonal injury and SE epilepsy models, two animal models that recapitulate many aspects of TBI- and SE-induced epilepsy in humans respectively. Thereafter, we discuss aspiring strategies for targeting BDNF/TrkB signaling so as to prevent epilepsy following an insult or suppress its expression once developed. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.

Keywords: BDNF; Post-traumatic epilepsy; Temporal lobe epilepsy; TrkB.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Anticonvulsants / administration & dosage*
  • Brain-Derived Neurotrophic Factor / antagonists & inhibitors
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Drug Delivery Systems / methods*
  • Epilepsy / drug therapy*
  • Epilepsy / metabolism*
  • Humans
  • Membrane Glycoproteins / antagonists & inhibitors
  • Membrane Glycoproteins / metabolism*
  • Receptor, trkB / antagonists & inhibitors
  • Receptor, trkB / metabolism*

Substances

  • Anticonvulsants
  • Brain-Derived Neurotrophic Factor
  • Membrane Glycoproteins
  • BDNF protein, human
  • Receptor, trkB
  • tropomyosin-related kinase-B, human